{"id":446586,"title":"Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T12:19:17.427000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-01-24.html?wbdisable=false","snippet":"Notice: Multiple Additions to the Prescription Drug List (PDL) Date: January 24, 2022 Our file number: 22-100898-943 The purpose of this Notice of Amendment is to notify about the additions of Anifrolumab, Avalglucosidase alfa, Dostarlimab, Fostemsavir, Palovarotene and…","rawSnapshotUrl":"/api/snapshots/raw/446586","browseUrl":"https://replay.healtharchive.ca/job-6/20260103121917/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-01-24.html?wbdisable=false#ha_snapshot=446586","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}